**Mast cell amines and inosine-induced vasoconstriction in the rat hind limb**

A. M. Northover and B. J. Northover

Department of Pharmaceutical Sciences, School of Applied Sciences, De Montfort University, Leicester LE1 9BH, UK

CA Corresponding Author
Fax: (+44) (0) 116 2577135

Introduction

Despite the fact that adenosine generally acts as a vasodilator in mammalian vascular beds, both adenosine and its main metabolite inosine have been shown to cause vasoconstriction in the rat perfused hind limb and in hamster cheek pouch arterioles. Adenosine can also contract strips isolated from rat tail arteries. Such responses have been shown to involve the release of mast cell amines and may result from stimulation of the adenosine type 3 (A3) receptors, which have been demonstrated to occur in mast cells. In the present work we have attempted to discover the type of adenosine receptor which is responsible for inosine-induced vasoconstriction in the rat perfused hind limb. A gelatin-containing physiological salt solution (GPSS) was used as perfusate, rather than blood, in order to eliminate the possible effects of 5-hydroxytryptamine (5HT) which may be released from rat platelets. Inosine was used in preference to adenosine since previous workers have shown that arterioles constrict in response to inosine over a wide range of concentrations, whereas adenosine constricts at low concentrations but at higher concentrations may dilate blood vessels. The types of receptor involved have been explored with the aid of various adenosine and 5HT receptor agonists and antagonists.

Methods

Female rats weighing approximately 250 g were killed by inhalation of chloroform vapour. The abdomen and thorax were opened using a ventro-lateral incision after which the vasculature was heparinized via an intra-cardiac injection. Subsequently, the left iliac artery, both renal arteries and the aorta proximal to the renal arteries were all ligated. A stainless steel cannula (1.07 mm OD), which offered no measurable resistance to flow at 10 ml/min, was then inserted into the right iliac artery via an incision in the aorta distal to the renal arteries, and was tied in place. Perfusate was then pumped into the right iliac artery at a rate of...
10 ml/min, and allowed to drain away through a hole cut in the inferior vena cava. Perfusion pressures were recorded from a Condon manometer connected to the perfusion line and via a strain gauge pressure transducer connected to a Multitrace 2 recorder (Lectromed, UK). A paper speed of 25 mm/min was used for the 1 min period immediately following bolus injections of various adenosine receptor agonists or of 5HT. These were delivered into the stream of perfusate using a back-to-back syringe system to minimize injection artefacts. Compounds to be tested as possible antagonists were added to the GPSS at the start of the experiment. All preparations were perfused for an initial stabilizing period of 10 min. Then, after recording baseline perfusion pressure for 3 min, 2.7 mg inosine in 0.2 ml normal saline (NS, 0.9% NaCl) was injected. Perfusion pressures thereafter were recorded continuously for 5 min. After perfusing for a further 5 min, to allow time for the effects of inosine to cease, the baseline pressure was again recorded and a control injection of 0.2 ml NS was given. Finally, this procedure was repeated with a bolus injection of 5HT (400 μg in 0.2 ml NS). Pilot experiments indicated that these doses of inosine and 5HT were necessary to produce suitable pressor responses. Preliminary experiments showed, as have those of previous workers, that the pressor response to inosine vanishes after approximately three injections have been made into the same preparation. Therefore, only one inosine, one NS and one 5HT response (where relevant) were recorded from each animal.

Experiments were also performed using the rat perfused tail vascular bed. For this, male rats weighing approximately 350 g were killed and heparinized as above. Both renal arteries and both iliac arteries were ligated in this case. After ligating the aorta proximally, the steel cannula was inserted into the tail artery via the distal aorta. Experiments then followed the protocol described above.

GPSS had the following composition (mM): NaCl, 138; KCl, 5; NaHCO3, 10.1; MgCl2, 1.06; NaH2PO4, 0.416; CaCl2, 2; glucose, 10; plus 2% gelatin, giving pH 7.4. Perfusates were gassed throughout with 95% O2 and 5% CO2 and were delivered at 37°C.

Compounds added to the GPSS were Nnitro-L-arginine methyl ester (L-NAME), a nitric oxide (NO) synthase inhibitor;9 cyproheptadine, a mixed histamine and 5HT receptor blocker;10 compound 48/80, which degranulates mast cells;11 8-cyclopentyl-1,3 dipropylxanthine (DPCPX), a relatively specific A1 receptor antagonist;12 or 8-phenyltheophylline (8PT), a mixed A1/A2 receptor antagonist.13 In addition to inosine two other putative adenosine receptor agonists were tested in the hind limb. There were N6-cyclopentyladenosine (CPA), which acts primarily via A1 receptors,14 and ido-benzyl-5-N-methyl carboxamidoadenosine (IB-MECA), which shows a much greater affinity for A3 than for either A1 or A2 receptors.15 These two compounds were administered in dimethyl sulphoxide (DMSO) diluted 1 + 19 with NS. Control injections in such preparations, therefore, were with DMSO + NS (1 + 19) rather than with NS alone.

All pressure recordings were made at the same amplification and paper speed, so they could be compared directly with each other. In order to compensate for any residual injection artefact, responses to each agonist were expressed (in arbitrary units) as the difference between the trace areas (Fig. 1) displayed above and below the pre-injection baseline, and after subtracting the response area for NS alone (or DMSO + NS) shown in the same preparation. Values for the maximum amplitude (A) reached were determined as shown in Fig. 1.

**Chemicals**

Inosine, 5HT creatinine sulphate, DPCPX, compound 40/80, 8PT, and CPA were obtained from Sigma Chemical Co. Ltd (Poole, UK); cyproheptadine HCl from Merck Sharp & Dohme Ltd

![Figure 1](image-url)

**FIG. 1.** Diagrammatic representation of a typical pressor response to a bolus injection of inosine (2.7 mg) in the rat hind limb perfused with GPSS + L-NAME (100 μg). Recordings were made on 1 mm squared paper. The pressor response to inosine in NS was calculated as the difference between the number of squares in the shaded area above the baseline minus the number of squares in the shaded area below the baseline. The equivalent numbers of squares (above and below the baseline) after an injection of NS (0.2 ml) was calculated from the same preparation. The response to NS alone was then subtracted from the response to inosine in NS. Final results were expressed in arbitrary units (Fig. 2 and Table 1). The maximum amplitude of the response (in mm) was determined at A.
Inosine and 5HT were dissolved in NS. L-NAME, compound 48/80 and cyproheptadine were added to GPSS as aqueous solutions. DPCPX, 8PT, CPA and IB-MECA were each initially dissolved in DMSO. The final concentration of DMSO in a perfusate was always <0.05%.

Statistics
Significant differences ($p < 0.05$) were determined using Bonferroni’s test for comparing several treatment groups with one control group.

Results
Responses to inosine and 5HT
In experiments using rat hind limb vessels perfused in vitro at constant rate with GPSS, a bolus of inosine (2.7 mg) caused a pressor response that began to wane after the first minute. There was no evidence that inosine produced any vasodilatation. A transient fall in perfusion pressure, however, occurred after each injection of NS. Hence this residual injection artefact needed to be compensated for in the responses to inosine and 5HT. Consequently the magnitude of the NS response was routinely deducted from that recorded after giving inosine or 5HT in the same animal. The pressor effect of 5HT (400 μg), unlike that due to inosine, continued to increase slowly for about 5 min. Because of these differing time courses, we decided to present the results obtained using area units. However, the maximum pressor amplitudes attained during the first minute after injection of either inosine or 5HT were closely related to the corrected areas of the pressor responses, but are not separately presented. The pressor effects of inosine and 5HT measured over the first minute post-injection were $54.1 \pm 15.3$ and $141.8 \pm 32.9$ area units respectively. Similar results were obtained with the rat tail vessels perfused with GPSS, where the pressor responses to inosine and to 5HT were $17.0 \pm 13.9$ and $231.6 \pm 45.8$ area units respectively. Mean starting perfusion pressures with GPSS flowing at 10 ml/min in the hind limb and tail vascular beds were approximately 34 and 70 mmHg respectively. When L-NAME (100 μM) was present in the GPSS perfusing the hind limb, the pressor responses to inosine and to 5HT were increased slightly to values of 61.3 $\pm$ 9.6 and 192.0 $\pm$ 30.7 area units respectively. This suggests that when NO-synthase was still active a slight dilatory effect from endogenous NO$^{14}$ may have blunted the net vasoconstriction that was produced by both inosine and 5HT. In all subsequent experiments L-NAME was added to the GPSS.

Effects of cyproheptadine and compound 48/80
Inclusion of cyproheptadine (1 μM) or compound 48/80 (1 μg/ml) in an L-NAME-containing GPSS significantly reduced the pressor effects of both injected inosine (Fig. 2) and 5HT (Table 1), suggesting that the pressor effects of inosine were attributable to 5HT released from a source within or adjacent to the vasculature.

Effects of specific adenosine receptor antagonists and agonists
When 8PT (1 μM) or DPCPX (1 μM) was included in an L-NAME-containing GPSS the response to inosine in the hind limb vessels was significantly reduced (Fig. 2). The specific A1 mediated vasoconstriction is shown in Fig. 2. The vasopressor effect of inosine (2.7 mg) in the rat hind limb, and its modification by pre-treatment with cyproheptadine (cypro, 1 μM), compound 48/80 (1 μg/ml), 8PT (1 μM) or DPCPX (0.1 μM). *$p < 0.05$, Bonferroni’s test, compared with the value for inosine alone. $n = 7–14$.

| Treatment       | $n$ | Response (in area units)$^{ab}$ |
|------------------|----|---------------------------------|
| 5HT              | 13 | $206.5 \pm 29.2$                |
| 5HT + cypro      | 7  | $-9.7 \pm 56.3^c$               |
| 5HT + 48/80      | 8  | $44.8 \pm 30.2^c$               |

$^a$ Results are mean ± SEM.  
$^b$ For details see Methods.  
$^c$ Significant difference compared with 5HT alone ($p < 0.05$, Bonferroni’s test).
receptor agonist CPA (500 μg) caused virtually no change in perfusion pressure (−0.5 ± 26.0 area units, n = 6). This was converted to a small depressor effects (−9.0 ± 14.3 area units, n = 3) after pre-treatment with compound 48/80 (1 μg/ml), but the difference from CPA responses without compound 48/80 pre-treatment was not statistically significant. The highly potent and specific A3 agonist IB-MECA (5 μg), exerted a statistically insignificant haemodynamic effect using this protocol (−16.7 ± 41.8 area units, n = 3).

Discussion
Most adenosine receptor agonists can relax most types of vascular smooth muscle.1 This effect is exerted, at least partly, via direct stimulation of both the muscular A1 receptors, which can open both KATP channels17,18 and Kchk channels18 and via the muscular A2 receptors, which activate adenylylcyclase.19 Vasodilatation occurring during periods of ischaemia is associated with, and partly due to, the increased concentrations of adenosine and its metabolite inosine20,21 which occur in the vicinity of blood vessels under these circumstances.22–24 Exogenous inosine can also dilate the coronary blood vessels.25 The vasoconstrictor responses to inosine which we report here, therefore, although confirming previous work,2–4 are rather atypical, but not peculiar to the rat, having been observed also in the hamster.2,4

The amount of inosine that was required to cause vasoconstriction in the present experiments (2.7 mg) was quite high, but not surprisingly so, since K values for inosine at A1, A2 and A3 receptors are reported to be in the 20–50 μM range.15 Furthermore, about 1 mg of adenosine is required to constrict blood vessels in the rat hind limb during perfusion with a physiological salt solution, whereas 30 μg is sufficient to cause vasoconstriction during perfusion with blood.26 These same workers have demonstrated the presence of 5HT in venous effluent collected during treatment with adenosine, but they did not speculate upon the site of origin of the 5HT. Perivascular mast cells are one obvious possibility, but coronary artery endothelial cells also contain, and may actually secrete, 5HT.27 Circulating platelets provide another source of 5HT when blood is used as the perfusate.8

Adenosine itself has been shown to stimulate granule/amine release from various types of mast cells.28–32 Inosine has a similar effect, but only at higher concentrations.30,32 Moreover, mast cells are normally present in the adventitial layer of various mammalian arteries.33,34 Since rat mast cell granules contain 5HT,35 adenosine receptor agonists that are delivered via the blood vessel lumen should be able to release 5HT from mast cells in the wall, provided that they can readily penetrate the intimal and medial layers of the wall, or reach the adventitia via the capillaries. Since 5HT is predominantly a vasoconstrictor,36 it is entirely possible that vasoconstrictor responses to adenosine receptor agonists that are seen in blood vessels of the rat hind limb, are due to released 5HT. Indeed, in the present experiments inosine lost its vasopressor effect after pre-treatment with cyproheptadine or with compound 48/80. Our evidence, therefore, supports a mast cell origin for the 5HT.

If inosine releases 5HT from adventitial mast cells, as the foregoing results would suggest, then it remains to decide which class of adenosine receptor was responsible. The fact that pre-treatment with either 8PT (a mixed A1/A2 antagonist),13 or with DPCPX (a selective A1 receptor antagonist),12 was able to prevent the pressor response to inosine suggests that it was A1 receptor activation which caused the release of 5HT here. Previous work on rat omental mast cells has indicated that degranulation occurs in response to selective A1 receptor agonists,32 including CPA. However, in the present experiments CPA produced no net effect on the perfusion pressure. This may have been because of a slower penetration of CPA than of inosine through the intimal and media layers of blood vessel walls on its way to the adventitia. In other words, CPA may not have stimulated adventitial mast cells powerfully enough to overcome the direct vasodilatory action which is likely to have been produced by CPA via A1/A2 receptors on the muscle cells (or the endothelial cells) of the wall. Of relevance in this connection is that on rat isolated aortae CPA was found to exert a net relaxant effect which was attributable to activation of endothelial A2 receptors.37

IB-MECA is claimed to be a selective A3 receptor agonist, the Ki values at A1, A2 and A3 receptors being 54 ± 5 nM, 56 ± 8 nM and 1.1 ± 0.3 nM respectively.15 In contrast, at A3 receptors inosine shows a Ki value approximately 50 000-fold higher than IB-MECA.15 On this basis, therefore, if inosine had caused its effects in the present experiments via A3 receptors, one would have expected IB-MECA to have mimicked inosine, but at a 50 000-fold lower concentration. In fact, IB-MECA failed to mimic the effect of inosine at a concentration
of 1000-fold less than that of the effective dose of inosine. It seems unlikely, therefore, that A3 receptors are involved. Similarly, IBMEC-A had no degranulating effect on omentum mast cells in vitro.32 Such a lack of response may merely reflect poor tissue penetration. Nevertheless, so far we have failed to obtain any evidence that A2 receptor stimulation was responsible for the release of mast cell amines in our experiments. This contrasts with the findings of some previous workers6,34 under different experimental conditions. These discrepancies are so far unexplained, but it may be relevant that the IBMEC-induced hypotension which occurs in cats was attributable to the activation of A1 and A2 receptors rather than of A3 receptors.38 Hopefully, with the advent of more specific adenosine receptor agonists these divergent observations will be explained.

References

1. Haddy FJ, Scott JB. Metabolically linked vasoactive chemicals in local regulation of blood flow. Physiol Rev 1968; 48: 688–707.
2. Sakai K, Akima M. Vasoinconstriction after adenosine and inosine in the rat isolated hindlimb abolished by blockade of tryptaminergic mechanisms. Naunyn-Schmiedeberg's Arch Pharmacol 1978; 302: 55–59.
3. Doyle MP, Linden J, Duling BR. Nucleoside-induced arteriolar constriction: a mast cell-dependent response. Am J Physiol 1994; 266: H2042–H2050.
4. Shepherd RK, Duling BR. Inosine-induced vasoinconstriction is mediated by histamine and thromboxane derived from mast cells. Am J Physiol 1996; 270: H560–H566.
5. Brown CM, Collis ME. Adenosine contracts the isolated rat tail artery by releasing endogenous 5-hydroxytryptamine. Eur J Pharmacol 1981; 76: 275–277.
6. Shepherd RK, Linden J, Duling BR. Adenosine-induced vasoinconstriction in vivo. Role of the mast cell and A3 adenosine receptor. Circ Res 1996; 78: 627–634.
7. Ramkumar V, Stiles GL, Beaver MA, Ali H. The A1 adenosine receptor is the unique adenosine receptor which facilitates release of allergic mediators in mast cells. J Biol Chem 1993; 268: 16887–16890.
8. Yang BC, Mehta JL. Platelets increase the tone of quiescent rat aortic rings by release of serotonin and potentiate the subsequent contracile response to norepinephrine. J Cardiovasc Pharmacol 1994; 23: 387–394.
9. Bees DD, Palmer RMJ, Schultz R, Hudson HE, Moncada S. Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol 1990; 101: 746–752.
10. Selby H, Somogyi A. Effect of cyclophosphamide upon acute inflammation produced by various agents. Med Pharm Exp 1967; 17: 255–263.
11. Horder GL. The effect of compound 48/80 on the rat mast cell. J Path Bact 1969; 90: 599–605.
12. Bruns RE, Ferguson JH, Badger EW, Bristol JA, Santay LA, Hartman JD, Hays SJ, Huang CC. Binding of the A1-selective adenosine antagonist 8-cyclopentyl-1,3-dipropylxanthine to rat brain membranes. Naunyn-Schmiedeberg's Arch Pharmacol 1987; 335: 59–63.
13. Daly JW. Adenosine receptors: targets for future drugs. J Med Chem 1982; 25: 197–207.
14. Hamilton HW, Taylor MD, Steffen RP, Halseen SJ, Bruns RE. Correlation of adenosine receptor affinities and cardiovascular activity. Life Sci 1987; 41: 2295–2302.
15. Gallo-Rodriguez C, Ji XD, Melman N, Siegman BD, Sanders LH, Olina J, Fisher B, Pu Q, Olah ME, van Galen PJM, Stiles GL, Jacobson KA. Structure-activity relationships of N-benzyladenosine-5'-mononucleotides as A1 selective adenosine agonists. J Med Chem 1994; 37: 636–646.
16. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43: 109–142.
17. Dart C, Standen NB. Adenosine-activated potassium current in smooth muscle cells isolated from the pig coronary artery. J Physiol 1993; 471: 767–786.
18. Kurachi Y. G protein regulation of cardiac muscarinic potassium channel. Am J Physiol 1995; 269: C821–C830.
19. Collis, MK. Haurani SMO. Adenosine receptor types. Trends Pharmacol Sci 1993; 14: 560–566.
20. Jacob MJ, Berne RM. Metabolism of purine derivatives by the isolated cat heart. Am J Physiol 1960; 198: 322–326.
21. Rubio R, Berne RM, Katai M. Release of adenosine in reactive hyperemia of the dog heart. Am J Physiol 1969; 216: 56–62.
22. Dibson JG Jr, Rubio R, Berne RM. Role of adenine nucleotides, adenosine and inorganic phosphate in the regulation of skeletal muscle blood flow. Circ Res 1971; 29: 375–384.
23. Berne RM, Rubio R, Curnish RR. Release of adenosine from ischemic myocardium. Effect on cerebral vascular resistance and incorporation into cerebral adenine nucleotides. Circ Res 1974; 35: 262–271.
24. Schrader J, Haddy FJ, Gerlach E. Release of adenosine, inosine and hypoxanthine from the isolated guinea pig heart during hypoxia, flow-autoregulation and reactive hyperemia. Pflogers Arch 1977; 369: 1–6.
25. Jones CE, Mayer JR. Nonmetabolically coupled coronary vasodilatation during inosine infusion in dogs. Am J Physiol 1980; 238: H669–H674.
26. Sakai K, Akima M, Matsushita H. Femoral vascular responses to purines and pyrimidines: release of 5-hydroxytryptamine by purine derivatives in isolated, cross-circulated rat hindlimb. Japan J Pharmacol 1979; 29: 243–251.
27. Burnstock G, Lincoln J, Feher E, Hwpwood AM, Kirkpatrick K, Milner P, Ralevic V. Serotonin is localized in endothelial cells of coronary arteries and released during hypoxia: a possible new mechanism for hypoxia-induced vasodilatation of the rat heart. Experientia 1988; 44: 705–707.
28. Marquardt DL, Parker CW, Sullivan TJ. Potentiation of mast cell mediator release by adenosine. J Immunol 1978; 120: 871–878.
29. Hughes PJ, Holgate ST, Church MK. Adenosine inhibits and potentiates IgE-dependent histamine release from human lung mast cells by an A1 adenosine receptor mediated mechanism. Biochem Pharmacol 1984; 33: 3847–3852.
30. Church MK, Hughes PJ, Vrdey CJ. Studies on the receptor mediating cyclic AMP-independent enhancement by adenosine of IgE-dependent mediator release from rat mast cells. Br J Pharmacol 1986; 87: 243–242.
31. John MJ, Maurer K, Gensheimer HP, Schwabe U. Dual actions of adenosine on rat peritoneal mast cells. Naunyn-Schmiedebergs Arch Pharmacol 1987; 335: 555–560.
32. Northover AM, Northover BJO. Degranulation of cat mast cells by A1 receptor agonists in vitro. Mediators Inflamm 1996; 5: 341–346.
33. Raul J, Dahlén SE, Smedegård G, Hedqvist P. An intravital microscopic model for mast cell-dependent inflammation in the hamster cheek pouch. Acta Physiol Scand 1989; 135: 95–105.
34. Pozard JR, Platttzke HJ, Schuurman HJ. Mast cell degranulation following adenosine A1 receptor activation in rat. Eur J Pharmacol 1996; 298: 293–297.
35. Sanyal RK, West GB. The role of histamine and 5-hydroxytryptamine in injury. Int Arch Allergy 1965; 26: 363–372.
36. Gorevic PD, Marshak RE, Bremmur RB. The mechanism of the cardiovascular effects of 5-hydroxytryptamine by BOL 148 and sodium salicylate in the human subject. Br J Pharmacol 1957; 12: 498–503.
37. Prentice DJ, Haurani SMO. Activation of multiple sites by adenosine analogues in the rat isolated aorta. Br J Pharmacol 1996; 118: 1509–1517.
38. Patel RM, Ramage AG. Investigation of the haemodynamic effects of the selective adenosine A1 receptor agonist iodobenzyl-5-Nethy carbamidoadenosine, IBMEC-A, in anaesthetized cats. Br J Pharmacol 1997; 120: 160.

Received 6 January 1997; accepted in revised form 3 February 1997